These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27525648)

  • 41. Tumor necrosis factor-alpha induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway.
    Li G; Barrett EJ; Barrett MO; Cao W; Liu Z
    Endocrinology; 2007 Jul; 148(7):3356-63. PubMed ID: 17446186
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice.
    Sartori C; Dessen P; Mathieu C; Monney A; Bloch J; Nicod P; Scherrer U; Duplain H
    Endocrinology; 2009 Dec; 150(12):5311-7. PubMed ID: 19819971
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
    Liu L; Liu J; Wong WT; Tian XY; Lau CW; Wang YX; Xu G; Pu Y; Zhu Z; Xu A; Lam KS; Chen ZY; Ng CF; Yao X; Huang Y
    Hypertension; 2012 Sep; 60(3):833-41. PubMed ID: 22868389
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.
    Kawakubo M; Tanaka M; Ochi K; Watanabe A; Saka-Tanaka M; Kanamori Y; Yoshioka N; Yamashita S; Goto M; Itoh M; Shirakawa I; Kanai S; Suzuki H; Sawada M; Ito A; Ishigami M; Fujishiro M; Arima H; Ogawa Y; Suganami T
    Sci Rep; 2020 Jan; 10(1):983. PubMed ID: 31969650
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acute glucosamine-induced insulin resistance in muscle in vivo is associated with impaired capillary recruitment.
    Wallis MG; Smith ME; Kolka CM; Zhang L; Richards SM; Rattigan S; Clark MG
    Diabetologia; 2005 Oct; 48(10):2131-9. PubMed ID: 16059714
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthetic (+)-antroquinonol exhibits dual actions against insulin resistance by triggering AMP kinase and inhibiting dipeptidyl peptidase IV activities.
    Hsu CY; Sulake RS; Huang PK; Shih HY; Sie HW; Lai YK; Chen C; Weng CF
    Br J Pharmacol; 2015 Jan; 172(1):38-49. PubMed ID: 24977411
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport.
    Goto M; Furuta S; Yamashita S; Hashimoto H; Yano W; Inoue N; Kato N; Kaku K
    J Diabetes Investig; 2018 Nov; 9(6):1261-1269. PubMed ID: 29754453
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
    Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
    Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.
    Omar B; Ahrén B
    Diabetes; 2014 Jul; 63(7):2196-202. PubMed ID: 24962916
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase.
    Duplain H; Burcelin R; Sartori C; Cook S; Egli M; Lepori M; Vollenweider P; Pedrazzini T; Nicod P; Thorens B; Scherrer U
    Circulation; 2001 Jul; 104(3):342-5. PubMed ID: 11457755
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose.
    Salheen SM; Panchapakesan U; Pollock CA; Woodman OL
    Pharmacol Res; 2015 Apr; 94():26-33. PubMed ID: 25697548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.
    Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
    Vascul Pharmacol; 2016 Apr; 79():16-23. PubMed ID: 26277250
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anagliptin inhibits neointimal hyperplasia after balloon injury via endothelial cell-specific modulation of SOD-1/RhoA/JNK signaling in the arterial wall.
    Li Q; Zhang M; Xuan L; Liu Y; Chen C
    Free Radic Biol Med; 2018 Jun; 121():105-116. PubMed ID: 29715547
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice.
    Shiuchi T; Iwai M; Li HS; Wu L; Min LJ; Li JM; Okumura M; Cui TX; Horiuchi M
    Hypertension; 2004 May; 43(5):1003-10. PubMed ID: 15037562
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhancing effects of anagliptin on myoblast differentiation and the expression of mitochondrial biogenetic factors in C2C12 mouse skeletal muscle cells.
    Han SE; Kim SJ; Kim YI; Nam-Goong IS; Jung HW; Kim ES
    Clin Exp Pharmacol Physiol; 2020 May; 47(5):903-906. PubMed ID: 31943324
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anagliptin suppresses diet-induced obesity through enhancing leptin sensitivity and ameliorating hyperphagia in high-fat high-sucrose diet fed mice.
    Kohno D; Furusawa K; Kitamura T
    Endocr J; 2020 May; 67(5):523-529. PubMed ID: 32009061
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle.
    Arnés L; González N; Tornero-Esteban P; Sancho V; Acitores A; Valverde I; Delgado E; Villanueva-Peñacarrillo ML
    Int J Mol Med; 2008 Jul; 22(1):127-32. PubMed ID: 18575785
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.
    Gault VA; Lennox R; Flatt PR
    Diabetes Obes Metab; 2015 Apr; 17(4):403-13. PubMed ID: 25580570
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
    Matsubara J; Sugiyama S; Sugamura K; Nakamura T; Fujiwara Y; Akiyama E; Kurokawa H; Nozaki T; Ohba K; Konishi M; Maeda H; Izumiya Y; Kaikita K; Sumida H; Jinnouchi H; Matsui K; Kim-Mitsuyama S; Takeya M; Ogawa H
    J Am Coll Cardiol; 2012 Jan; 59(3):265-76. PubMed ID: 22240132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.